127 related articles for article (PubMed ID: 25294903)
1. DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.
Klajic J; Busato F; Edvardsen H; Touleimat N; Fleischer T; Bukholm I; Børresen-Dale AL; Lønning PE; Tost J; Kristensen VN
Clin Cancer Res; 2014 Dec; 20(24):6357-66. PubMed ID: 25294903
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
Staalesen V; Leirvaag B; Lillehaug JR; Lønning PE
Clin Cancer Res; 2004 May; 10(10):3438-43. PubMed ID: 15161699
[TBL] [Abstract][Full Text] [Related]
3. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
[TBL] [Abstract][Full Text] [Related]
4. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
[TBL] [Abstract][Full Text] [Related]
5. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
Nordgard SH; Alnaes GI; Hihn B; Lingjaerde OC; Liestøl K; Tsalenko A; Sørlie T; Lønning PE; Børresen-Dale AL; Kristensen VN
Int J Cancer; 2008 Aug; 123(3):577-85. PubMed ID: 18498133
[TBL] [Abstract][Full Text] [Related]
6. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
Dejeux E; Rønneberg JA; Solvang H; Bukholm I; Geisler S; Aas T; Gut IG; Børresen-Dale AL; Lønning PE; Kristensen VN; Tost J
Mol Cancer; 2010 Mar; 9():68. PubMed ID: 20338046
[TBL] [Abstract][Full Text] [Related]
9. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
10. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.
Weiss D; Basel T; Sachse F; Braeuninger A; Rudack C
Mol Carcinog; 2011 Sep; 50(9):680-8. PubMed ID: 21563216
[TBL] [Abstract][Full Text] [Related]
12. [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer].
Zemliakova VV; Zhevlova AI; Strel'nikov VV; Liubchenko LN; Vishnevskaia IaV; Tret'iakova VA; Zaletaev DV; Nemtsova MV
Mol Biol (Mosk); 2003; 37(4):696-703. PubMed ID: 12942643
[TBL] [Abstract][Full Text] [Related]
13. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
[TBL] [Abstract][Full Text] [Related]
14. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].
Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
17. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.
Chen X; Liu L; Mims J; Punska EC; Williams KE; Zhao W; Arcaro KF; Tsang AW; Zhou X; Furdui CM
Epigenetics; 2015; 10(6):545-61. PubMed ID: 25961636
[TBL] [Abstract][Full Text] [Related]
18. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
19. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
[TBL] [Abstract][Full Text] [Related]
20. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
